3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended March 31, 2020:
+Added: The following table summarizes the activity, by month, during the three months ended June 30, 2020:
Purchased (1)
9 unchanged sentences
Purchased Under
−Removed: January 34,817 $ 5.19 180,621 $ 7,820,088
−Removed: February 10,629 4.49 47,694 7,772,394
−Removed: March 119,430 (1) 3.74 446,384 7,326,010
+Added: April 60,144 $ 3.96 60,144 $ 7,117,585
+Added: May 43,078 3.81 43,078 6,953,582
+Added: June 38,241 (1) 3.40 38,241 6,823,744
Total 141,463 141,463
(1) Of this amount, 3,235 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
−Removed: 10.1 Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between A.J.
−Removed: Kazimi and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.11 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No.
−Removed: 001-33637) and incorporated herein by reference.
−Removed: 10.2 Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Martin E.
−Removed: Cearnal and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.12 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No.
−Removed: 001-33637) and incorporated herein by reference.
−Removed: 10.3 Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Leo B.
−Removed: Pavliv and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.13 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No.
−Removed: 001-33637) and incorporated herein by reference.
−Removed: 10.4 Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Michael P.
−Removed: Bonner and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.14 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No.
−Removed: 001-33637) and incorporated herein by reference.
−Removed: 10.5 Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between James L.
−Removed: Herman and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.15 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No.
−Removed: 001-33637) and incorporated herein by reference.
+Added: Submission of Matters to a Vote of Security Holders
+Added: At its meeting on May 5, 2020 our Board of Directors determined to hold future non-binding shareholder advisory votes on executive compensation every three years until the next non-binding advisory vote on the frequency of shareholder votes on executive compensation, which is required to occur no later that the Company's 2026 annual meeting of shareholders.
+Added: Such determination is consistent with the previous recommendation of the Board of Directors and the preference of Company shareholders, as represented by their votes at the annual meeting of shareholders on May 5, 2020.
+Added: 10.1* A men dment Nu mber 2 to t h e A mended and Restated 2007 Long-Term Incentive Co mpensation Plan.
+Added: 10.2* Amendment Number 2 to the Amended and Restated 2007 Director's Incentive Compensation Plan.
+Added: 10.3* Payment Protection Program Note dated April 20 , 2020, by and between Cumberland Pharmac euticals Inc.
+Added: and Pinnacle Bank .
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: May 22, 2020 By:
+Added: August 14, 2020 By:
/s/ Michael Bonner
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.